Slowing of peripheral motor nerve conduction was ameliorated by aminoguanidine in streptozocin-induced diabetic rats

European Journal of Endocrinology

Volumn 134, Issue 4, 1996, Pages 467-473

  Miyauchi, Yosuke ^a   Shikama, Hisataka ^a   Takasu, Toshiyuki ^a   Okamiya, Hideaki ^a   Umeda, Masako ^a   Hirasaki, Eiko ^a   Ohhata, Isao ^a   Nakayama, Hidetaka ^b   Nakagawa, Shoichi ^b  

^a ASTELLAS PHARMA INC   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGUANIDINE; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; MALE; MOTOR NERVE; NERVE CONDUCTION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

EID: 0029938105     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1340467     Document Type: Article

References (29)

1. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1983;318:1315-21
2. Monnier VM, Kohn RR, Cerami A. Accelerated age-related browning of human collagen in diabetes mellitus. Proc Natl Acad Sci USA 1984;81:583-7
3. Nakayama H, Taneda S, Kuwajima S, Aoki S, Kuroda Y, Misawa K, et al. Production and characterization of antibodies to advanced glycation products on proteins. Biochem Biophys Res Commun 1989;162:740-5
4. Nakayama H, Matsuhashi T, Kuwajima S, Aoki S, Kuroda Y, Itoh T, et al. Immunochemical detection of advanced glycation end products in lens crystallins from streptozocin-induced diabetic rats. Diabetes 1993;42:345-50
5. Matsuhashi T, Nakayama H, Itoh T, Kuwajima S, Aoki S, Atsumi T, et al. Immunochemical detection of advanced glycation end products in renal cortex from STZ-induced diabetic rat. Diabetes 1993;42:826-32
6. Makita Z, Vlassara H, Cerami A, Bucala B. Immunochemical detection of advanced glycosylation endproducts in vivo. J Biol Chem 1992;267:5133-8
7. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986;232:1629-32
8. Makita Z, Vlassara H, Rayfield E, Cartwright K, Friedman E, Rodby R, et al. Hemoglobin-AGE: a circulation marker of advanced glycosylation. Science 1992;258:651-3
9. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991;40:1328-34
10. Edelstein D, Brownlee M. Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats. Diabetologia 1992;35:96-7
11. Ellis EN, Good BH. Prevention of glomerular basement membrane thickening by aminoguanidine in experimental diabetes Mellitus. Metabolism 1991;40:1016-9
12. Kihara M, Schmelzer JD, Poduslo JF, Curran GL, Nickander KK, Low PA. Aminoguanidine effects on nerve blood flow. vascular permeability, electrophysiology, and oxygen free radicals. Proc Natl Acad Sci USA 1991;88:6107-11
13. Yagihashi S, Kamijo M, Baba M, Yagihashi N, Nagai K. Effect of aminoguanidine on functional and structural abnormalities in peri-pheral nerve of STZ-induced diabetic rats. Diabetes 1992;41: 47-52
14. Sharma AK, Thomas PK. Peripheral nerve structures and function in experimental diabetes. J Neurosci 1974;23:1-15
15. +-ATPase activity in superior cervical ganglion of STZ-diabetic rat and prevention by aldose reductase inhibition. Diabetes 1986;35:1106-8
16. Johnson RN, Metcalf PA, Baker JR. Fructosamine: a new approach to the estimation of serum glycosylprotein. An index of diabetic control. Clin Chim Acta 1982;127:87-95
17. Greene DA, Lattimer SA, Sima AAF. Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complication. N Engl J Med 1987;316:599-606
18. Winegard AI. Banting lecture 1986: does a common mechanism induce the diverse complications of diabetes? Diabetes 1987;36:396-406
19. Das PK, Bray GM, Aguayo AJ, Prasminsky M. Dimished ouabain-sensitive sodium-potassium ATPase activity in sciatic nerve of rats with streptozotocin-induced diabetes. Exp Neurol 1976;53: 285-8
20. +-ATPase pumping activity is not directly linked to myo-inositol levels after sorbinil treatment in lenses of diabetic rats. Diabetes 1987;36:1414-9
21. Ao S, Shingu Y, Kikuchi C, Takano Y, Nomura K, Fujiwara T, et al. Characterization of a novel aldose reductase inhibitor, FR74366, and its effects on diabetic cataract and neuropathy in the rat. Metabolism 1991;40:77-87
22. Stribling D, Mirrees DJ, Harrison HE, Earl DCN. Properties of ICI 128,436, a novel aldose reductase inhibitor, and its effects on diabetic complications in the rat. Metabolism 1985;34:336-44
23. Van Der Zee CEEM. Van Der Hoop RG, Gispen WH. Beneficial effect of Org 2766 in treatment of peripheral neuropathy in streptozocin-induced diabetic rats. Diabetes 1989;38:225-30
24. Cameron NF, Cotter MA, Dines K, Love A. Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 1992; 35:946-50
25. Low PA, Schmelzer JD, Ward KK, Yoa JK. Experimental chronic hypoxic neuropathy; relevance to diabetic neuropathy. Am J Physiol 1986;250:E94-9
26. Malik RA, Masson EA, Sharma AK, Lye RH, Ah-See AK, Compton AM, et al. Hypoxic neuropathy: relevant to human diabetic neuropathy. Diabetologia 1990;33:311-8
27. Low PA, Tuck RR, Dyck PJ, Schmelzer JD, Yao JK. Prevention of some electrophysiologic and biochemical abnormalities with oxygen supplementation in experimental diabetic neuropathy. Proc Natl Acad Sci USA 1984;81:6894-8
28. Odetti PR, Borgoglio A, De Pascale A, Rolandi R, Adezati L. Prevention of diabetes-increased aging effect on rat collagen-linked fluorescence by aminoguanidine and rutin. Diabetes 1900; 39:796-801
29. Vlassara H, Brownlee M, Cerami A. Accumulation of diabetic rat peripheral nerve myelin by macrophages increases with the presence of advanced glycosylation endproducts. J Exp Med 1984;160:197-207